Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment
A prospective, single center, single arm, phase II clinical trial of Pyrotinib combined with pemetrexed plus carboplatin in the first-line treatment of patients with HER2 mutant or amplified recurrent / metastatic non-small cell lung cancer
Lung Cancer, Non-small Cell
DRUG: Pyrotinib combined with pemetrexed plus carboplatin
PFS, progression free survival, from the first cycle of treatment (day one) to two month after the last cycle (each cycle is 21 days)]
A prospective, single center, single arm, phase II clinical trial of Pyrotinib combined with pemetrexed plus carboplatin in the first-line treatment of patients with HER2 mutant or amplified recurrent / metastatic non-small cell lung cancer